The comparator was an effective medicine
Nicholls and colleagues compared tirzepatide with dulaglutide in people with type 2 diabetes and established atherosclerotic cardiovascular disease. This blinded trial used an active medicine with previous cardiovascular evidence, rather than placebo. After eligibility exclusions, 13,165 participants contributed to the main analysis. The outcome combined cardiovascular death, heart attack and stroke.
Two statistical questions had different answers
Events occurred in 12.2% with tirzepatide and 13.1% with dulaglutide. The hazard ratio was 0.92, with a 95.3% confidence interval from 0.83 to 1.01. The interval met the prespecified noninferiority requirement, whose upper boundary was 1.05, but did not establish superiority. Gastrointestinal adverse events were more frequent with tirzepatide.
Translate the conclusion carefully
Noninferiority means the comparison satisfied the study’s chosen margin; it does not mean the treatments are identical. A numerically lower event percentage also does not, by itself, demonstrate superiority. When reading a long-term claim, keep the comparator, endpoint and uncertainty interval together instead of ranking medicines from the percentages alone.
Duration cannot supply a missing comparison
The trial did not compare planned stopping and restarting strategies, so it cannot establish a generic cycle. Nor does its selected patient group support unlimited safety claims for healthy people or unregulated research products. We reviewed the complete indexed abstract of the Eli Lilly-funded December 2025 publication; publisher full text was unavailable. The illustration represents follow-up conceptually and contains no treatment schedule.